$ 7.56
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of TERN is 21 and suggests 181% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
